- CRISPR Therapeutics CRSP presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.
- CTX130 was well tolerated across all dose levels. There were no cases of Graft versus Host Disease (GvHD), no dose-limiting toxicities (DLTs), and no instances of tumor lysis syndrome (TLS).
- Needham notes that 95% of beta-thalassemia (TDT) achieved sustained transfusion independence (TI), with the remaining two showing a significantly reduced transfusion burden.
- An overall response rate (ORR) of 70% with a 30% complete response (CR) rate was reported in patients at dose levels≥3 (300M and 900M cells).
- Chardan has updated its model, increasing POS for exa-cel in TDT and SCD to 75% from 65% and 60%, respectively.
- Needham believes the impressive and durable efficacy observed with CTX001 makes it a competitive therapeutic even if Bluebird Bio Inc's BLUE beti-cel enters the market first.
- Read Next: FDA Advisory Committee Backs Bluebird Bio's Blood Disorder Gene Therapy.
- HC Wainwright says beti-cels' efficacy and safety profile are comparable to CTX001, although the modalities are different.
- Chardan believes exa-cel is positioned to overtake beti-cel (given its lead in SCD and as BLUE has pulled out of Europe), betting on CRSP's partner Vertex Pharmaceuticals Inc's VRTX global infrastructure.
- Price Action: CRSP shares are down 13.5% at $55.15 during the market session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.